A 6-week randomized trial found that tirzepatide significantly reduced energy intake, appetite, and cravings in adults with ...

Under the renewed deal, Bayer and Tsinghua University will work to enhance the drug discovery and development process across ...

More data leads to more precise answers, and the biopharma industry has at its disposal more data than ever before.

Though caution is required when the data haven't been published, it could be a landmark in the drug's journey toward FDA ...

Compass Pathways' Phase 3 COMP-360 data met primary endpoints but disappointed vs analyst expectations. See why investors ...

Kymera on Wednesday said Sanofi won't advance KT-474, which in late 2023 entered Phase 2 studies trials in patients with the inflammatory skin diseases hidradenitis suppurativa and atopic dermatitis.

In this interview, Richard J. Nowak, MD, MS, principal investigator of the MINT trial of inebilizumab for generalized myasthenia gravis (gMG), discusses the trial’s key findings, including significant ...

Psilocybin, the main psychoactive ingredient in magic mushrooms, could alleviate depression for at least five years after ...

CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for ...

Abcentra LLC (Abcentra), a clinical stage biotechnology company specializing in coronary artery disease, today ...